Concizumab: A Breakthrough Prophylaxis for Hemophilia B and A with Inhibitors
The World Federation of Hemophilia (WFH) shared a breakthrough for hemophilia with inhibitors on X:
”While treatment options have advanced, people with hemophilia B and inhibitors still face major gaps. A new review explores concizumab, a subcutaneous prophylaxis option that could help close that gap and improve outcomes.”
Read the full article here.
Despite advancements in hemophilia treatment, people with hemophilia A or B (HA, HB) and inhibitors face significant unmet needs, particularly in prophylaxis.
While emicizumab addresses prophylaxis for HA with inhibitors, no such option existed for HB until the arrival of concizumab.
This novel, subcutaneous treatment—approved since 2023 in countries like Canada, Australia, Japan, and Switzerland—is the first prophylactic therapy for HB with inhibitors.
The drug also offers new hope for HA patients with persistent bleeds on emicizumab.
With a unique mechanism of action, convenient multi-dose pen delivery, and quick washout, concizumab is poised to improve quality of life and long-term outcomes in this historically underserved population.
Hemostasis Today, your daily update on the latest advancements in the field of Hemophilia.
-
Sep 5, 2025, 14:06Thrombosis Update: VTE Death Rate 3X Higher in Los Angeles Jails Than General Population
-
Sep 4, 2025, 22:00Shivani Modi Highlights SOHO 2025 Study Linking Elevated WBC Counts to Increased Thrombosis Risk
-
Sep 4, 2025, 22:00Cancer, Clots and Communication: Register Now for The Upcoming Webinar on CAT!
-
Sep 4, 2025, 11:52PARTHENOPE Trial: A New Benchmark in Risk Score Validation
-
Sep 4, 2025, 09:46SOHO 2025: Exploring AI in Hematology and Oncology
-
Sep 5, 2025, 14:04Melasma Treatment Advances: Non-Ablative Laser and Tranexamic Acid Combination Explained
-
Sep 5, 2025, 12:55RENOVE and API-CAT Trials: Exploring Secondary VTE Prevention
-
Sep 5, 2025, 12:18Lucia Masarova Presents Results of Phase III SURPASS-ET Trial at SOHO 2025: Ropeg's Efficacy for Essential Thrombocythemia
-
Sep 5, 2025, 06:28Digital Twin Study Predicts Higher Thrombotic Recurrence with DOACs vs VKAs in APS Patients
-
Sep 4, 2025, 22:00Asfand Yar Cheema at SOHO 2025: PSM Cohort Study on GLP-1 Agonist Therapy Key Clinical Outcomes for Polycythemia Vera
-
Sep 2, 2025, 13:53Cost-Effective Strategies to Reduce Anaemia Highlighted in The Lancet Haematology
-
Sep 2, 2025, 13:04Ischemic Stroke or TIA Linked to Higher Femoral Fracture Risk
-
Sep 2, 2025, 12:51Treatment of Deep Brain AVMs Tied to Increased Hemorrhagic Stroke Risk
-
Aug 29, 2025, 09:03Vasculearn Network: New 2025 High Blood Pressure Guidelines Are Here
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Sep 5, 2025, 14:12EAHAD Podcast: Reducing Pain and Distress in Children Receiving Emicizumab
-
Sep 5, 2025, 03:18Pier Mannuccio Mannucci on How Green Spaces and Physical Activity Can Help Prevent Heart Failure
-
Sep 5, 2025, 02:15Abdul Mannan Explains How DOACs Can Confuse Lupus Anticoagulant Testing
-
Sep 4, 2025, 11:55Sumyea Kabir Highlights the Critical Role of Safe Donors in Blood Transfusion Safety
-
Sep 3, 2025, 14:18Living with Factor V Deficiency: Helen’s Inspiring Story on Haemnet Haemcast